Prevalence, Risk Factors And Location Of Skip Metastasis In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis
Authors Qiu Y, Fei Y, Liu J, Liu C, He X, Zhu N, Zhao W, Zhu J
Received 7 January 2019
Accepted for publication 13 August 2019
Published 25 September 2019 Volume 2019:11 Pages 8721—8730
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Rituraj Purohit
Yuxuan Qiu,1,* Yuan Fei,1,* Jingyan Liu,2 Chang Liu,3 Xin He,4 Ning Zhu,5 Wan-jun Zhao,1 Jing-qiang Zhu1
1Department of Thyroid & Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 3Public Policy and Administration, Department of Government, London School of Economics and Political Science, London, UK; 4West China School of Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 5Library and Information Science, School of Information Management, Nanjing University, Nanjing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jing-qiang Zhu
Department of Thyroid & Parathyroid surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan 610041, People’s Republic of China
Background: Skip metastasis is a special type in cervical lymph node metastasis (LNM) of patients diagnosed with papillary thyroid carcinoma (PTC) which induced poor prognosis. There are few studies about skip metastasis and conclusions remained uncertain. Therefore, this study aims to explore the frequency and to investigate risk factors of skip metastasis in PTC.
Methods: Through searching the keyword by PubMed and Embase databases which articles published up to 1st August 2018 about skip metastasis in papillary thyroid carcinoma, we extract data in order to assure whether those materials meet the criteria.
Results: The prevalence of skip metastasis is 12.02% in light of our meta-analysis of 18 studies with 2165 patients. The upper pole location (RR = 3.35, 95% CI =1.65–6.79, P = 0.0008) and tumors size ≤1 cm (RR = 2.65, 95% CI =1.50–4.70, P = 0.0008) are significantly associated with skip metastasis, whereas lymphovascular invasion (RR = 0.33, 95% CI =0.15–0.75, P = 0.0083) exists lower rate of skip metastasis. Multifocality, gender, age, bilaterality, thyroiditis and Extrathyroidal extension (ETE) are insignificantly associated with skip metastasis. Level II and level III are the most frequently affected areas.
Conclusion: The lateral compartment should be carefully examined especially for those PTC patients who present primary tumors in the upper lobe with a primary tumor size ≤10 mm which could be detected with skip metastasis.
Keywords: papillary thyroid carcinoma, skip metastasis, lateral neck dissection, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]